US20040097703A1 - Wt1 modified peptide - Google Patents

Wt1 modified peptide Download PDF

Info

Publication number
US20040097703A1
US20040097703A1 US10/471,835 US47183503A US2004097703A1 US 20040097703 A1 US20040097703 A1 US 20040097703A1 US 47183503 A US47183503 A US 47183503A US 2004097703 A1 US2004097703 A1 US 2004097703A1
Authority
US
United States
Prior art keywords
cells
peptide
cancer
antigen
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/471,835
Inventor
Haruo Sugiyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
International Institute of Cancer Immunology Inc
Original Assignee
Haruo Sugiyama
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haruo Sugiyama filed Critical Haruo Sugiyama
Publication of US20040097703A1 publication Critical patent/US20040097703A1/en
Assigned to INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. reassignment INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SUGIYAMA, HARUO
Priority to US12/552,660 priority Critical patent/US8105604B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Definitions

  • the present invention relates to a cancer antigen based on the product of Wilms' tumor suppresser gene WT1.
  • This cancer antigen is useful as an anticancer vaccine against cancers of the blood such as leukemia, myelodysplastic syndrome, multiple myeloma and malignant lymphoma, solid cancers such as gastric cancer, colon cancer, lung cancer, breast cancer, germinal cell cancer, liver cancer, skin cancer, bladder cancer, prostate cancer, uterine cancer, cervical carcinoma and ovarian cancer, as well as any cancer that expresses WT1.
  • the immune mechanism for eliminating foreign objects from the body generally consists of humoral immunity, in which is involved macrophages that function as antigen-presenting cells that recognize an antigen, helper T-cells that activate other T-cells by recognizing antigens presented by said macrophages and producing various lymphokines, and B lymphocytes that differentiate into antibody-producing cells due to the action of said lymphokines; and, cellular immunity, by which killer T-cells (cytotoxic T-cells (CTL)), which have differentiated as a result of being presented with an antigen, attack and destroy target cells.
  • CTL cytotoxic T-cells
  • cancer immunity is thought to mainly be the result of cellular immunity involving killer T-cells.
  • precursor T-cells which have recognized cancer antigen presented in the form of a complex of major histocompatibility complex (MHC) class I (MHC class I antigen, also referred to as HLA antigen in the case of humans) and cancer antigen, differentiate and proliferate, and the resulting killer T-cells that have formed attack and destroy the cancer cells.
  • MHC class I antigen major histocompatibility complex
  • HLA antigen also referred to as HLA antigen in the case of humans
  • cancer antigen differentiate and proliferate, and the resulting killer T-cells that have formed attack and destroy the cancer cells.
  • the cancer cells present a complex of MHC class I antigen and cancer antigen on their cell surface, and this is targeted by the killer T-cells (Cur. Opin. Immunol., 5, 709, 1993; Cur. Opin. Immunol., 5, 719, 1993; Cell, 82, 13, 1995; Immun
  • the aforementioned cancer antigen presented by MHC class I antigen on the cancer cells serving as the target cells is thought to be a peptide composed of about 8-12 amino acids formed as a result of antigen protein synthesized within cancer cells being processed by intracellular protease (Cur. Opin. Immunol., 5, 709, 1993; Cur. Opin. Immunol., 5, 719, 1993; Cell, 82, 13, 1995; Immunol. Rev., 146, 167, 1995).
  • the tumor suppresser gene WT1 of Wilms tumor has been isolated from chromosome 11p13 as one of the causative genes of Wilms tumor based on analysis of the WAGR syndrome that occurs as a complication of Wilms tumor, aniridia, urogenital abnormalities, mental retardation and so forth (Gessler, M., et al., Nature, Vol. 343, p. 774-778 (1990)).
  • Its genomic DNA is about 50 kb and is composed of 10 exons, while its cDNA is about 3 kb.
  • the amino acid sequence estimated from cDNA is as shown in Sequence ID No. 1 (Mol. Cell. Biol., 11, 1707, 1991).
  • the WT1 gene is expressed with high frequency in human leukemia, and when leukemia cells are treated with WT1 antisense oligomer, the growth of the cells is inhibited (Japanese Unexamined Patent Publication No. 9-104627). Thus, WT1 gene is thought to act to promote the growth of leukemia cells. Moreover, WT1 is also highly expressed in solid cancers such as gastric cancer, colon cancer, lung cancer, breast cancer, germinal cell cancer, liver cancer, skin cancer, bladder cancer, prostate cancer, uterine cancer, cervical carcinoma and ovarian cancer (Japanese Patent Application No. 9-191635), and the WT1 gene has been demonstrated to be a novel tumor marker in leukemia and solid cancers.
  • an object of the present invention is to provide a peptide that is promising as a cancer vaccine and which has higher activity than previously known cancer-specific antigen peptides.
  • WT1 modified peptide having an amino acid sequence in which the second amino acid Met of the aforementioned known amino acid sequence (Sequence ID No. 2) is changed to Tyr, namely Cys Tyr Thr Trp Asn Gln Met Asn Leu (Sequence ID No. 3), has higher activity, thereby leading to completion of the present invention.
  • the present invention provides a peptide (WT1 modified peptide) consisting of 9-30 amino acids and comprising the following amino acid sequence: Cys Tyr Thr Trp Asn Gln Met Asn Leu (Sequence ID No. 3).
  • This peptide is preferably a polypeptide consisting of 9-12 amino acids and comprising the amino acid sequence indicated in Sequence ID No. 3 and, more preferably, a peptide consisting of the amino acid sequence indicated in Sequence ID No. 3.
  • the present invention provides a cancer vaccine having for its active ingredient the aforementioned WT1 modified peptide.
  • the present invention also provides a DNA vaccine against cancer having for its active ingredient DNA coding for the aforementioned peptide.
  • the present invention provides antigen-presenting cells on which presented a complex of HLA antigen (MHC class I antigen) and the aforementioned peptide.
  • the present invention also provides cytotoxic T-cells that recognize a complex of HLA antigen and the aforementioned peptide.
  • FIG. 1 is a graph showing the cell killing effects (specific cytolytic activity) on C1R2402 target cells (T), either pulsed or not pulsed with peptide, by effecter cells (E) stimulated with WT1 wild peptide (Sequence ID No. 2) or the WT1 modified peptide of the present invention (Sequence ID No. 3).
  • the black circles indicate the cytolytic effect on C1R2402 target cells pulsed with wild peptide by effecter cells stimulated with WT1 modified peptide
  • the black squares indicate the cytolytic effect on C1R2404 target cells pulsed with wild peptide by effecter cells stimulated with WT1 wild peptide
  • the white circles indicate the cytolytic effect on C1R2402 target cells not pulsed with wild peptide by effecter cells stimulated with WT1 modified peptide
  • the white squares indicate the cytolytic effect on C1R2402 target cells not pulsed with wild peptide by effecter cells stimulated with WT1 wild peptide.
  • FIG. 2 is a graph showing the cytolytic activity on acute myelocytic leukemia cells endogenously expressing WT1 antigen or on acute myelocytic leukemia cells not expressing WT1 antigen by effecter cells stimulated with WT1 wild peptide or the WT1 modified peptide of the present invention.
  • FIG. 3 is a graph showing the cell killing effects (specific cytolytic activity) on C1R2402 target cells, either pulsed or not pulsed with peptide, by effecter cells stimulated with WT1 wild peptide or the WT1 modified peptide of the present invention.
  • the black circles indicate the cytolytic effect on C1R2402 cells pulsed with wild peptide by effecter cells stimulated with WT1 modified peptide
  • the black squares indicate the cytolytic effect on C1R2402 target cells pulsed with wild peptide by effecter cells stimulated with WT1 wild peptide
  • the white circles indicate the cytolytic effect on C1R2402 target cells not pulsed with wild peptide by effecter cells stimulated with WT1 modified peptide
  • the white squares indicate the cytolytic effect on C1R2402 target cells not pulsed with wild peptide by effecter cells stimulated with WT1 wild peptide.
  • FIG. 4 is a graph showing the cytolytic activity on lung cancer cell lines endogenously expressing WT1 or not expressing WT1 by effecter cells stimulated with WT1 wild peptide or the WT1 modified peptide of the present invention.
  • FIG. 5 is a graph showing the inhibitory effects of anti-HLA class I antibody, anti-HLA class II antibody and anti-CD8 antibody on the cell killing effects (specific cytolytic activity) on C1R2402 target cells pulsed with wild peptide by effecter cells stimulated by WT1 wild peptide or the WT1 modified peptide of the present invention.
  • the peptide of the present invention is a peptide consisting of 9-30 amino acids that comprises the amino acid sequence consisting of the 9 amino acids shown in Sequence ID No. 3.
  • the peptide is preferably a peptide consisting of 9-12 amino acids that comprises the amino acid sequence shown in Sequence ID No. 3 and, more preferably, is a peptide having rules (motifs) in the sequence of antigen peptide presented by binding to HLA antigen at that time (J. Immunol., 152, p. 3913, 1994; Immunogenetics, 41, p. 178, 1995; J. Immunol., 155, p. 4307, 1994; J. Immunol., 155, p. 4749, 1995).
  • the peptide is most preferably a peptide consisting of an amino acid sequence of the 9 amino acids shown in Sequence ID No. 3.
  • the aforementioned “peptide comprising the amino acid sequence shown in Sequence ID No. 3” is specifically, for example, a peptide comprising the amino acid sequence shown in Sequence ID No. 3 and extending in the direction of the N-terminal and/or the direction of the C-terminal from the applicable position on WT1 (Sequence ID No. 1) (position nos. 235-243) or from the corresponding position on human WT1 (NCBI Database Accession No. XP012009), that has activity as a cancer antigen peptide.
  • An example of a method for measuring the activity of the cancer antigen peptide of the present invention is the method described in J. Immunol., 154, p. 2257, 1995. The following provides an explanation of an outline of this method using the case of the type of HLA being HLA-A24 as an example.
  • peripheral blood lymphocytes are isolated from a person positive for HLA-A24 antigen.
  • CTL cytotoxic T-cells
  • This induction of CTL can be investigated by, for example, measuring the amounts of various cytokines (e.g., IFN- ⁇ ) produced by the CTL by reacting with the complex of antigen peptide and HLA-A24.
  • induction of CTL can also be investigated by a method in which the cytotoxicity of the CTL is measured with respect to antigen peptide-presenting cells labeled with 51 Cr or Europium ( 51 Cr Release Assay, Int. J. Cancer, 58, p. 317, 1994; Europium Release Assay, J. Immunol., 154, p. 3991, 1995).
  • induction of CTL can also be investigated by referring to the examples described later.
  • the present invention also relates to a cancer vaccine that has the aforementioned antigen as its active ingredient.
  • This vaccine can be used for the prevention or treatment of cancers of the blood such as leukemia, myelodysplastic syndrome, multiple myeloma and malignant lymphoma, as well as solid cancers such as gastric cancer, colon cancer, lung cancer, breast cancer, germinal cell cancer, liver cancer, skin cancer, bladder cancer, prostate cancer, uterine cancer, cervical carcinoma and ovarian cancer.
  • this vaccine can be applied to patients positive for HLA-A24.
  • This vaccine can be administered orally or parenterally by for example, intraperitoneal, subcutaneous, intracutaneous, intramuscular, intravenous or intranasal administration.
  • administration of the vaccine of the present invention can also be carried out by a method in which monocytes are collected from the peripheral blood of a patient, dendritic cells are extracted from the monocytes, the dendritic cells are pulsed with the peptide of the present invention and then returned to the patient by subcutaneous administration and so forth.
  • cytotherapy cytotherapy or dendritic cell (DC) therapy
  • DC dendritic cell
  • the vaccine in addition to the peptide administered as the aforementioned active ingredient, may also contain pharmaceutically allowable carriers such as a suitable adjuvant (Clin-Microbiol. Rev., 7, 277-289, 1994), examples of which include a mineral gel like aluminum hydroxide, a surfactant like phosphorous lecithin and a pluronic polyole, a polyanion, a peptide and an oily emulsion.
  • the vaccine may contain other aggregates mixed into liposomes or blended into polysaccharide or the vaccine.
  • the dosage is typically 0.1 ⁇ g/kg to 1 mg/kg per day.
  • DNA that codes the aforementioned polypeptide vaccine can also be used as a vaccine (DNA vaccine). Namely, after inserting nucleic acids, and preferably DNA, that contain nucleic acids that encode the WT1 modified peptide of the present invention into a suitable vector, and preferably an expression vector, cancer immunity can be imparted by administering the vector to an animal.
  • a suitable vector and preferably an expression vector
  • cancer immunity can be imparted by administering the vector to an animal.
  • WO 00/6602 or J. Immunol., 160, p. 1717, 1998 and so forth should be referred to for the specific technique used for this DNA vaccine.
  • the present invention relates to antigen-presenting cells on which a complex of HLA antigen and the aforementioned peptide is presented.
  • antigen-presenting cells on which a complex of HLA antigen and the aforementioned peptide is presented.
  • HLA-A24 antigen HLA antigen
  • CTL cytotoxic T-cells
  • the antigen-presenting cells used in cytotherapy are produced by isolating cells having the ability to present antigen from tumor patients, pulsing these cells with peptide of the present invention outside the body, and causing a complex of HLA antigen and the peptide of the present invention to be presented on the surface of the cells.
  • the “cells having the ability to present antigen” are cells that express HLA antigen capable of presenting the peptide of the present invention on the surface of the cells, dendritic cells are preferable since they are considered to have high antigen-presenting ability.
  • the peptide of the present invention that is used to pulse the aforementioned cells having the ability to present antigen may not only be in the form of a peptide, but rather may also be in the form of DNA or RNA that encodes said peptide.
  • a specific method for preparing the antigen-presenting cells of the present invention can be referred to in, for example, Cancer Immunol. Immunother., 46, 82, 1998, J. Immunol., 158, p. 1796, 1997, and Cancer Res., 59, p. 1184, 1999.
  • dendritic cells lymphocytes are isolated from the peripheral blood of a tumor patients using the Fycoll method, and after subsequently removing the non-adhered cells, dendritic cells are derived from the adhered cells by culturing in the presence of GM-CSF and IL-4, after which the antigen-presenting cells of the present invention can be prepared by pulsing the dendritic cells by culturing with the peptide of the present invention.
  • insertion can be carried out by referring to, for example, Cancer Res., 56, p. 5672, 1996 or J. Immunol., 161, p. 5607, 1998 in the case of DNA, or by referring to J. Exp. Med., 184, p. 465, 1996 in the case of RNA.
  • these antigen-presenting cells can be used as the active ingredient of a tumor therapeutic agent.
  • the treatment agent preferably comprises physiological saline, phosphate-buffered saline (PBS) or medium and so forth.
  • administration methods include intravenous administration, subcutaneous administration and intracutaneous administration.
  • the present invention also relates to cytotoxic T-cells (CTL) that recognize a complex of HLA antigen and the aforementioned peptide.
  • CTL cytotoxic T-cells
  • the CTL of the present invention can be effectively used in the adoptive immunotherapy described below.
  • the CTL of the present invention can be used as the active ingredient of a tumor therapeutic agent.
  • the therapeutic agent preferably comprises physiological saline, phosphate-buffered saline (PBS) or medium and so forth.
  • administration methods include intravenous administration, subcutaneous administration and intracutaneous administration.
  • Peripheral blood mononuclear cells were isolated from HLA-A*2402-positive donors and distributed among the wells of a 24-well plate at 2 ⁇ 10 6 cells/well followed by the addition of WT1 wild peptide or WT1 modified peptide to a concentration of 20 ⁇ M and culturing for 1 week.
  • the medium used at this time consisted of 45% RPMI, 45% AIV, 10% FCS 1 ⁇ non-essential amino acids and SM/PCG. Following the aforementioned culturing, the cells were adjusted to 2 ⁇ 10 6 cells/well and used as responder cells.
  • peripheral blood mononuclear cells were similarly isolated from the same HLA-A*2402-positive donors and then peptide-pulsed by culturing for 4 days with one of the aforementioned peptides at 20 ⁇ M. After then irradiating at 30 Gy, the cells were adjusted to 4 ⁇ 10 6 cells/well and used as stimulator cells.
  • WT1+/A*2402+ cells leukemia cells from AML patient #1
  • WT1 ⁇ /A*2402+ cells leukemia cells from AML patient #2
  • WT1+/A*2402 ⁇ cells leukemia cells from AML patient #3
  • WT1 ⁇ /A*2402 ⁇ cells leukemia cells from AML patient #4
  • Example 2 The same experiment as Example 1 was carried out using effector cells prepared from peripheral blood mononuclear cells of different healthy donors positive for HLA-A*2402. Those results are shown in FIG. 3.
  • the cytotoxic activity of effector cells stimulated with WT1 wild peptide or WT1 modified peptide was tested on a cancer cell line associated with lung cancer that endogenously expresses WT1 antigen (target cells) using the 51 Cr release method.
  • RERF-LCAI WT1+/A*2402+
  • LC1sq WT1+/A*2402+
  • 11-18 WT1 ⁇ /A*2402+
  • LK87 WT1+/A*2402 ⁇
  • Effector cells stimulated with WT1 wild peptide or WT1 modified peptide were confirmed to be CD8-positive killer cells that bind to HLA class I by a blocking assay using antibody.
  • the antibodies used consisted of anti-HLA class I antibody, anti-HLA class II antibody and anti-CD8 antibody.
  • Effector cells (E) prepared in the same manner as Example 1 and target cells (T) in the form of C1R2402 cells or C1R2402 cells pulsed with WT1 wild peptide, both labeled with 51 Cr, were mixed with antibody at an E:T ratio of 20:1 and then cultured for 4 hours followed by measurement of the degree of cell lysis according to the 51 Cr release method. Those results are shown in FIG. 5.
  • WT1 modified peptide demonstrated stronger binding affinity for HLA-A*2402 than the WT1 wild peptide.
  • the peptide of the present invention was proven to unquestionably function as a cancer antigen, and cause the induction and proliferation of killer T-cells (cancer cell cytotoxic T-cells) against cancer cells.
  • the cancer antigen peptide of the present invention is useful as a cancer vaccine against leukemia and solid cancers accompanying an increased expression of the WT1 gene.

Abstract

The present invention discloses a cancer antigen peptide comprising the following amino acid sequence: Cys Tyr Thr Trp Asn Gln Met Asn Leu (Sequence ID No. 3), a cancer vaccine having this for its active ingredient, and a DNA vaccine having for its active ingredient DNA that codes for this peptide.

Description

    TECHNICAL FIELD
  • The present invention relates to a cancer antigen based on the product of Wilms' tumor suppresser gene WT1. This cancer antigen is useful as an anticancer vaccine against cancers of the blood such as leukemia, myelodysplastic syndrome, multiple myeloma and malignant lymphoma, solid cancers such as gastric cancer, colon cancer, lung cancer, breast cancer, germinal cell cancer, liver cancer, skin cancer, bladder cancer, prostate cancer, uterine cancer, cervical carcinoma and ovarian cancer, as well as any cancer that expresses WT1. [0001]
    • DESCRIPTION OF THE RELATED ART
  • The immune mechanism for eliminating foreign objects from the body generally consists of humoral immunity, in which is involved macrophages that function as antigen-presenting cells that recognize an antigen, helper T-cells that activate other T-cells by recognizing antigens presented by said macrophages and producing various lymphokines, and B lymphocytes that differentiate into antibody-producing cells due to the action of said lymphokines; and, cellular immunity, by which killer T-cells (cytotoxic T-cells (CTL)), which have differentiated as a result of being presented with an antigen, attack and destroy target cells. [0002]
  • At present, cancer immunity is thought to mainly be the result of cellular immunity involving killer T-cells. In cancer immunity affected by killer T-cells, precursor T-cells, which have recognized cancer antigen presented in the form of a complex of major histocompatibility complex (MHC) class I (MHC class I antigen, also referred to as HLA antigen in the case of humans) and cancer antigen, differentiate and proliferate, and the resulting killer T-cells that have formed attack and destroy the cancer cells. At this time, the cancer cells present a complex of MHC class I antigen and cancer antigen on their cell surface, and this is targeted by the killer T-cells (Cur. Opin. Immunol., 5, 709, 1993; Cur. Opin. Immunol., 5, 719, 1993; Cell, 82, 13, 1995; Immunol. Rev., 146, 167, 1995). [0003]
  • The aforementioned cancer antigen presented by MHC class I antigen on the cancer cells serving as the target cells is thought to be a peptide composed of about 8-12 amino acids formed as a result of antigen protein synthesized within cancer cells being processed by intracellular protease (Cur. Opin. Immunol., 5, 709, 1993; Cur. Opin. Immunol., 5, 719, 1993; Cell, 82, 13, 1995; Immunol. Rev., 146, 167, 1995). [0004]
  • At present, although searches have been conducted for antigen proteins for various cancers, few have been verified to be cancer-specific antigens. [0005]
  • The tumor suppresser gene WT1 of Wilms tumor (WT1 gene) has been isolated from chromosome 11p13 as one of the causative genes of Wilms tumor based on analysis of the WAGR syndrome that occurs as a complication of Wilms tumor, aniridia, urogenital abnormalities, mental retardation and so forth (Gessler, M., et al., Nature, Vol. 343, p. 774-778 (1990)). Its genomic DNA is about 50 kb and is composed of 10 exons, while its cDNA is about 3 kb. The amino acid sequence estimated from cDNA is as shown in Sequence ID No. 1 (Mol. Cell. Biol., 11, 1707, 1991). [0006]
  • The WT1 gene is expressed with high frequency in human leukemia, and when leukemia cells are treated with WT1 antisense oligomer, the growth of the cells is inhibited (Japanese Unexamined Patent Publication No. 9-104627). Thus, WT1 gene is thought to act to promote the growth of leukemia cells. Moreover, WT1 is also highly expressed in solid cancers such as gastric cancer, colon cancer, lung cancer, breast cancer, germinal cell cancer, liver cancer, skin cancer, bladder cancer, prostate cancer, uterine cancer, cervical carcinoma and ovarian cancer (Japanese Patent Application No. 9-191635), and the WT1 gene has been demonstrated to be a novel tumor marker in leukemia and solid cancers. [0007]
  • Several cancer-specific antigen peptides consisting of a portion of the WT1 gene expression product are described in WO 00/06602, one particularly promising peptide is designated as D[0008] b, and the following amino acid sequence: Cys Met Thr Trp Asn Gln Met Asn Leu (Sequence ID No. 2) (referred to as “WT1 wild peptide” in the present invention) is described therein.
    • DISCLOSURE OF THE INVENTION
  • Thus, an object of the present invention is to provide a peptide that is promising as a cancer vaccine and which has higher activity than previously known cancer-specific antigen peptides. [0009]
  • As a result of earnestly conducting various studies to solve the above problems, the inventors of the present invention found that a peptide (referred to as “WT1 modified peptide”) having an amino acid sequence in which the second amino acid Met of the aforementioned known amino acid sequence (Sequence ID No. 2) is changed to Tyr, namely Cys Tyr Thr Trp Asn Gln Met Asn Leu (Sequence ID No. 3), has higher activity, thereby leading to completion of the present invention. [0010]
  • Thus, the present invention provides a peptide (WT1 modified peptide) consisting of 9-30 amino acids and comprising the following amino acid sequence: Cys Tyr Thr Trp Asn Gln Met Asn Leu (Sequence ID No. 3). This peptide is preferably a polypeptide consisting of 9-12 amino acids and comprising the amino acid sequence indicated in Sequence ID No. 3 and, more preferably, a peptide consisting of the amino acid sequence indicated in Sequence ID No. 3. [0011]
  • Moreover, the present invention provides a cancer vaccine having for its active ingredient the aforementioned WT1 modified peptide. [0012]
  • Moreover, the present invention also provides a DNA vaccine against cancer having for its active ingredient DNA coding for the aforementioned peptide. [0013]
  • In addition, the present invention provides antigen-presenting cells on which presented a complex of HLA antigen (MHC class I antigen) and the aforementioned peptide. [0014]
  • Moreover, the present invention also provides cytotoxic T-cells that recognize a complex of HLA antigen and the aforementioned peptide.[0015]
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a graph showing the cell killing effects (specific cytolytic activity) on C1R2402 target cells (T), either pulsed or not pulsed with peptide, by effecter cells (E) stimulated with WT1 wild peptide (Sequence ID No. 2) or the WT1 modified peptide of the present invention (Sequence ID No. 3). In the graph, the black circles indicate the cytolytic effect on C1R2402 target cells pulsed with wild peptide by effecter cells stimulated with WT1 modified peptide, the black squares indicate the cytolytic effect on C1R2404 target cells pulsed with wild peptide by effecter cells stimulated with WT1 wild peptide, the white circles indicate the cytolytic effect on C1R2402 target cells not pulsed with wild peptide by effecter cells stimulated with WT1 modified peptide, and the white squares indicate the cytolytic effect on C1R2402 target cells not pulsed with wild peptide by effecter cells stimulated with WT1 wild peptide. [0016]
  • FIG. 2 is a graph showing the cytolytic activity on acute myelocytic leukemia cells endogenously expressing WT1 antigen or on acute myelocytic leukemia cells not expressing WT1 antigen by effecter cells stimulated with WT1 wild peptide or the WT1 modified peptide of the present invention. [0017]
  • FIG. 3 is a graph showing the cell killing effects (specific cytolytic activity) on C1R2402 target cells, either pulsed or not pulsed with peptide, by effecter cells stimulated with WT1 wild peptide or the WT1 modified peptide of the present invention. In the graph, the black circles indicate the cytolytic effect on C1R2402 cells pulsed with wild peptide by effecter cells stimulated with WT1 modified peptide, the black squares indicate the cytolytic effect on C1R2402 target cells pulsed with wild peptide by effecter cells stimulated with WT1 wild peptide, the white circles indicate the cytolytic effect on C1R2402 target cells not pulsed with wild peptide by effecter cells stimulated with WT1 modified peptide, and the white squares indicate the cytolytic effect on C1R2402 target cells not pulsed with wild peptide by effecter cells stimulated with WT1 wild peptide. [0018]
  • FIG. 4 is a graph showing the cytolytic activity on lung cancer cell lines endogenously expressing WT1 or not expressing WT1 by effecter cells stimulated with WT1 wild peptide or the WT1 modified peptide of the present invention. [0019]
  • FIG. 5 is a graph showing the inhibitory effects of anti-HLA class I antibody, anti-HLA class II antibody and anti-CD8 antibody on the cell killing effects (specific cytolytic activity) on C1R2402 target cells pulsed with wild peptide by effecter cells stimulated by WT1 wild peptide or the WT1 modified peptide of the present invention.[0020]
    • DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • The peptide of the present invention is a peptide consisting of 9-30 amino acids that comprises the amino acid sequence consisting of the 9 amino acids shown in Sequence ID No. 3. Moreover, from the viewpoint of being presented by binding to HLA antigen, the peptide is preferably a peptide consisting of 9-12 amino acids that comprises the amino acid sequence shown in Sequence ID No. 3 and, more preferably, is a peptide having rules (motifs) in the sequence of antigen peptide presented by binding to HLA antigen at that time (J. Immunol., 152, p. 3913, 1994; Immunogenetics, 41, p. 178, 1995; J. Immunol., 155, p. 4307, 1994; J. Immunol., 155, p. 4749, 1995). Moreover, the peptide is most preferably a peptide consisting of an amino acid sequence of the 9 amino acids shown in Sequence ID No. 3. [0021]
  • Furthermore, the aforementioned “peptide comprising the amino acid sequence shown in Sequence ID No. 3” is specifically, for example, a peptide comprising the amino acid sequence shown in Sequence ID No. 3 and extending in the direction of the N-terminal and/or the direction of the C-terminal from the applicable position on WT1 (Sequence ID No. 1) (position nos. 235-243) or from the corresponding position on human WT1 (NCBI Database Accession No. XP012009), that has activity as a cancer antigen peptide. [0022]
  • An example of a method for measuring the activity of the cancer antigen peptide of the present invention is the method described in J. Immunol., 154, p. 2257, 1995. The following provides an explanation of an outline of this method using the case of the type of HLA being HLA-A24 as an example. First, peripheral blood lymphocytes are isolated from a person positive for HLA-A24 antigen. Next, by stimulating the peripheral blood lymphocytes by adding the peptide of the present invention in vitro, CTL (cytotoxic T-cells) are induced that specifically recognize the complex of the peptide of the present invention and HLA-A24 presented by the antigen-presenting cells. [0023]
  • This induction of CTL can be investigated by, for example, measuring the amounts of various cytokines (e.g., IFN-γ) produced by the CTL by reacting with the complex of antigen peptide and HLA-A24. In addition, induction of CTL can also be investigated by a method in which the cytotoxicity of the CTL is measured with respect to antigen peptide-presenting cells labeled with [0024] 51Cr or Europium (51Cr Release Assay, Int. J. Cancer, 58, p. 317, 1994; Europium Release Assay, J. Immunol., 154, p. 3991, 1995). Moreover, induction of CTL can also be investigated by referring to the examples described later.
  • The present invention also relates to a cancer vaccine that has the aforementioned antigen as its active ingredient. This vaccine can be used for the prevention or treatment of cancers of the blood such as leukemia, myelodysplastic syndrome, multiple myeloma and malignant lymphoma, as well as solid cancers such as gastric cancer, colon cancer, lung cancer, breast cancer, germinal cell cancer, liver cancer, skin cancer, bladder cancer, prostate cancer, uterine cancer, cervical carcinoma and ovarian cancer. In particular, this vaccine can be applied to patients positive for HLA-A24. This vaccine can be administered orally or parenterally by for example, intraperitoneal, subcutaneous, intracutaneous, intramuscular, intravenous or intranasal administration. [0025]
  • Moreover, administration of the vaccine of the present invention can also be carried out by a method in which monocytes are collected from the peripheral blood of a patient, dendritic cells are extracted from the monocytes, the dendritic cells are pulsed with the peptide of the present invention and then returned to the patient by subcutaneous administration and so forth. [0026]
  • This method is referred to as cytotherapy or dendritic cell (DC) therapy, and the section entitled “Antigen-Presenting Cells” described later should be referred to for further details. [0027]
  • The vaccine, in addition to the peptide administered as the aforementioned active ingredient, may also contain pharmaceutically allowable carriers such as a suitable adjuvant (Clin-Microbiol. Rev., 7, 277-289, 1994), examples of which include a mineral gel like aluminum hydroxide, a surfactant like phosphorous lecithin and a pluronic polyole, a polyanion, a peptide and an oily emulsion. Alternatively, the vaccine may contain other aggregates mixed into liposomes or blended into polysaccharide or the vaccine. The dosage is typically 0.1 μg/kg to 1 mg/kg per day. [0028]
  • In the present invention, DNA that codes the aforementioned polypeptide vaccine can also be used as a vaccine (DNA vaccine). Namely, after inserting nucleic acids, and preferably DNA, that contain nucleic acids that encode the WT1 modified peptide of the present invention into a suitable vector, and preferably an expression vector, cancer immunity can be imparted by administering the vector to an animal. WO 00/6602 or J. Immunol., 160, p. 1717, 1998 and so forth should be referred to for the specific technique used for this DNA vaccine. [0029]
  • In addition, the present invention relates to antigen-presenting cells on which a complex of HLA antigen and the aforementioned peptide is presented. In this example, although potent cell killing activity is observed due to stimulation with the peptide of the present invention, this is the result of the presence of antigen-presenting cells, on which a complex of the peptide of the present invention and HLA antigen (HLA-A24 antigen) is presented, within peripheral blood monocytes, and of the induction of CTL (cytotoxic T-cells) that specifically recognize these antigen-presenting cells. These antigen-presenting cells on which a complex of HLA antigen and the peptide of the present invention is presented are used effectively in cytotherapy (DC therapy) as described below. [0030]
  • The antigen-presenting cells used in cytotherapy are produced by isolating cells having the ability to present antigen from tumor patients, pulsing these cells with peptide of the present invention outside the body, and causing a complex of HLA antigen and the peptide of the present invention to be presented on the surface of the cells. Here, although there are no particular restrictions on the “cells having the ability to present antigen” provided they are cells that express HLA antigen capable of presenting the peptide of the present invention on the surface of the cells, dendritic cells are preferable since they are considered to have high antigen-presenting ability. [0031]
  • In addition, the peptide of the present invention that is used to pulse the aforementioned cells having the ability to present antigen may not only be in the form of a peptide, but rather may also be in the form of DNA or RNA that encodes said peptide. [0032]
  • A specific method for preparing the antigen-presenting cells of the present invention can be referred to in, for example, Cancer Immunol. Immunother., 46, 82, 1998, J. Immunol., 158, p. 1796, 1997, and Cancer Res., 59, p. 1184, 1999. In the case of using dendritic cells, lymphocytes are isolated from the peripheral blood of a tumor patients using the Fycoll method, and after subsequently removing the non-adhered cells, dendritic cells are derived from the adhered cells by culturing in the presence of GM-CSF and IL-4, after which the antigen-presenting cells of the present invention can be prepared by pulsing the dendritic cells by culturing with the peptide of the present invention. [0033]
  • In addition, in the case of preparing the antigen-presenting cells of the present invention by inserting DNA or RNA encoding the peptide of the present invention into the aforementioned cells having the ability to present antigen, insertion can be carried out by referring to, for example, Cancer Res., 56, p. 5672, 1996 or J. Immunol., 161, p. 5607, 1998 in the case of DNA, or by referring to J. Exp. Med., 184, p. 465, 1996 in the case of RNA. [0034]
  • These antigen-presenting cells can be used as the active ingredient of a tumor therapeutic agent. At that time, in order to maintain the stability of the antigen-presenting cells, the treatment agent preferably comprises physiological saline, phosphate-buffered saline (PBS) or medium and so forth. Examples of administration methods include intravenous administration, subcutaneous administration and intracutaneous administration. [0035]
  • Moreover, the present invention also relates to cytotoxic T-cells (CTL) that recognize a complex of HLA antigen and the aforementioned peptide. The CTL of the present invention can be effectively used in the adoptive immunotherapy described below. [0036]
  • Namely, in the case of melanoma, adoptive immunotherapy has been recognized to be therapeutically effective by culturing a large number of the patient's T-cells that have invaded the tumor in vitro, and then returning them to the patient (J. Natl. Cancer Inst., 86, 1159, 1994). In addition, in the case of mouse melanoma, inhibition of metastasis has been observed by stimulating spleen cells in vitro with tumor antigen peptide TRP-2, allowing specific CTL to proliferate in the tumor antigen peptide, and then administering said CTL to melanoma-transplanted mice (J. Exp. Med., 185, 453, 1997). This is based on the result of allowing CTL to proliferate in vitro that specifically recognize a complex of the HLA antigen of antigen-presenting cells and tumor antigen peptide. Thus, a treatment method in which patient peripheral blood lymphocytes are stimulated in vitro using the peptide of the present invention to increase tumor-specific CTL followed by returning these cells to the patient is thought to be useful. [0037]
  • In this manner, the CTL of the present invention can be used as the active ingredient of a tumor therapeutic agent. At that time, in order to maintain the stability of the CTL, the therapeutic agent preferably comprises physiological saline, phosphate-buffered saline (PBS) or medium and so forth. Examples of administration methods include intravenous administration, subcutaneous administration and intracutaneous administration. [0038]
  • The following examples serve to clarify the usefulness of the peptide of the present invention as a cancer antigen and cancer vaccine. [0039]
    • EXAMPLE 1
  • Peripheral blood mononuclear cells were isolated from HLA-A*2402-positive donors and distributed among the wells of a 24-well plate at 2×10[0040] 6 cells/well followed by the addition of WT1 wild peptide or WT1 modified peptide to a concentration of 20 μM and culturing for 1 week. The medium used at this time consisted of 45% RPMI, 45% AIV, 10% FCS 1× non-essential amino acids and SM/PCG. Following the aforementioned culturing, the cells were adjusted to 2×106 cells/well and used as responder cells.
  • On the other hand, other peripheral blood mononuclear cells were similarly isolated from the same HLA-A*2402-positive donors and then peptide-pulsed by culturing for 4 days with one of the aforementioned peptides at 20 μM. After then irradiating at 30 Gy, the cells were adjusted to 4×10[0041] 6 cells/well and used as stimulator cells.
  • The responder cells and stimulator cells prepared in the manner described above were then mixed and then cultured for 1 week following the addition of IL-2 at 50 U/ml. As a result, the status of the resulting cells were as shown in the following table. [0042]
    TABLE 1
    Peptide No. of cells CD4 CD8
    WT1 wild peptide 2.4 × 106/well  5% 35%
    WT1 modified 3.0 × 106/well 18% 38%
    peptide
  • Next, a killing assay was carried out in accordance with [0043] 51Cr release method (J. Immunol., 164, 1873, 2000). C1R2402 cells and C1R2402 cells pulsed with the aforementioned peptides were used for the target cells. Cells stimulated by WT1 wild peptide or WT1 modified peptide as previously described (effector cells (E)) were then allowed to act on each of these target cells (T) at an E:T ratio of 1, 5 of 20, followed by measurement of cell lysis. Those results are shown in FIG. 1. As is clear from this graph, cells stimulated with WT1 modified peptide exhibited a more potent cell killing activity than cells stimulated with WT1 wild peptide.
    • EXAMPLE 2
  • The cell killing activity of effector cells stimulated with WT1 wild peptide or WT1 modified peptide on leukemia cells that endogenously express WT1 antigen was tested according to the [0044] 51Cr release method. WT1+/A*2402+ cells (leukemia cells from AML patient #1), WT1−/A*2402+ cells (leukemia cells from AML patient #2), WT1+/A*2402− cells (leukemia cells from AML patient #3) and WT1−/A*2402− cells (leukemia cells from AML patient #4) were used for the target cells.
  • The effector cells (E) prepared in Example 1 and the aforementioned target cells (T) were mixed at an E:T ratio of 20:1 and cultured for 4 hours followed by measurement of the degree of cell lysis. Those results are shown in FIG. 2. [0045]
  • As is clear from this graph, although both the cells stimulated with WT1 wild peptide or WT1 modified peptide demonstrated cytotoxic activity on the WT1+/A*2402 cells, the level of that activity was higher for the WT1 modified peptide. [0046]
    • EXAMPLE 3
  • The same experiment as Example 1 was carried out using effector cells prepared from peripheral blood mononuclear cells of different healthy donors positive for HLA-[0047] A*2402. Those results are shown in FIG. 3.
  • As is clear from this graph, similar to Example 1, cells stimulated with WT1 modified peptide exhibited a more potent cytotoxic activity than cells stimulated with WT1 wild peptide. [0048]
    • EXAMPLE 4
  • The cytotoxic activity of effector cells stimulated with WT1 wild peptide or WT1 modified peptide was tested on a cancer cell line associated with lung cancer that endogenously expresses WT1 antigen (target cells) using the [0049] 51Cr release method. RERF-LCAI (WT1+/A*2402+), LC1sq (WT1+/A*2402+), 11-18 (WT1−/A*2402+) and LK87 (WT1+/A*2402−) cells were used for the target cells.
  • Effector cells (E) prepared in the same manner as Example 1 and the aforementioned target cells (T) labeled with [0050] 51Cr were cultured for 4 hours at an E:T ratio of 20:1 in the same manner as Example 2 followed by measurement of the degree of cell lysis. Those results are shown in FIG. 4.
  • As is clear from this graph, although both the cells stimulated with WT1 wild peptide or WT1 modified peptide demonstrated cytotoxic activity only on the WT1+/A*2402+ cells, the level of that activity was higher for WT1 modified peptide. [0051]
    • EXAMPLE 5
  • Effector cells stimulated with WT1 wild peptide or WT1 modified peptide were confirmed to be CD8-positive killer cells that bind to HLA class I by a blocking assay using antibody. The antibodies used consisted of anti-HLA class I antibody, anti-HLA class II antibody and anti-CD8 antibody. Effector cells (E) prepared in the same manner as Example 1 and target cells (T) in the form of C1R2402 cells or C1R2402 cells pulsed with WT1 wild peptide, both labeled with [0052] 51Cr, were mixed with antibody at an E:T ratio of 20:1 and then cultured for 4 hours followed by measurement of the degree of cell lysis according to the 51Cr release method. Those results are shown in FIG. 5.
  • As is clear from this graph, cytotoxic activity was blocked by anti-HLA class I antibody and anti-CD8 antibody for both the cells stimulated with WT1 wild peptide or WT1 modified peptide, indicating that the cells that exhibit cytotoxic activity are CD8-positive killer cells that bind to HLA class I. [0053]
    • EXAMPLE 6
  • The binding affinity of WT1 modified peptide and WT1 wild peptide to HLA-A*2402 was investigated. After treating C1RA2402 cells for 1 minute with a buffer solution (131 mM citric acid, 66 mM sodium phosphate, 290 m osmol, pH 3.3), the cells were neutralized by adding DMEM medium comprising 0.5% bovine serum albumin. After washing the cells with the medium, they were suspended at a concentration of 2×10[0054] 6 cells/ml in DMEM medium containing 200 nM β2-microglobulin (Sigma) and 0.5% bovine serum albumin. 15 μl of the cell suspension were mixed with 50 μl of the medium comprising various concentrations of WT1 peptide followed by incubating for 4 hours at room temperature. After washing the cells, they were stained with monoclonal antibody to HLA-A24 labeled with FITC (clone name: 7A12), and the amount of HLA-A24 expressed was analyzed with a flow cytometer FACS system. A similar procedure was performed on the antigen peptide of melanoma antigen pmel 15, which has been reported to bind to HLA-A*2402 (Ala Tyr Gly Leu Asp Phe Tyr Ile Leu) (Sequence ID No. 4) (J. Immunol., 154, 5994, 1995), and using this as a standard, the dissociation constants (Kd) of the WT1 peptides were calculated according to the method described in the literature (Immunogenetics, 51, 816, 2000). These results are shown in Table 2.
    TABLE 2
    Peptide Dissociation constant Kd (M)
    WT1 wild peptide 1.82 × 10−5
    WT1 modified peptide 6.40 × 10−7
  • As is clear from this table, WT1 modified peptide demonstrated stronger binding affinity for HLA-A*2402 than the WT1 wild peptide. [0055]
  • On the basis of the aforementioned results, the peptide of the present invention was proven to unquestionably function as a cancer antigen, and cause the induction and proliferation of killer T-cells (cancer cell cytotoxic T-cells) against cancer cells. Thus, the cancer antigen peptide of the present invention is useful as a cancer vaccine against leukemia and solid cancers accompanying an increased expression of the WT1 gene. [0056]
  • 1 4 1 449 PRT Mouse 1 Met Gly Ser Asp Val Arg Asp Leu Asn Ala Leu Leu Pro Ala Val Ser 5 10 15 Ser Leu Gly Gly Gly Gly Gly Gly Cys Gly Leu Pro Val Ser Gly Ala 20 25 30 Arg Gln Trp Ala Pro Val Leu Asp Phe Ala Pro Pro Gly Ala Ser Ala 35 40 45 Tyr Gly Ser Leu Gly Gly Pro Ala Pro Pro Pro Ala Pro Pro Pro Pro 50 55 60 Pro Pro Pro Pro His Ser Phe Ile Lys Gln Glu Pro Ser Trp Gly Gly 65 70 75 80 Ala Glu Pro His Glu Glu Gln Cys Leu Ser Ala Phe Thr Leu His Phe 85 90 95 Ser Gly Gln Phe Thr Gly Thr Ala Gly Ala Cys Arg Tyr Gly Pro Phe 100 105 110 Gly Pro Pro Pro Pro Ser Gln Ala Ser Ser Gly Gln Ala Arg Met Phe 115 120 125 Pro Asn Ala Pro Tyr Leu Pro Ser Cys Leu Glu Ser Gln Pro Thr Ile 130 135 140 Arg Asn Gln Gly Tyr Ser Thr Val Thr Phe Asp Gly Ala Pro Ser Tyr 145 150 155 160 Gly His Thr Pro Ser His His Ala Ala Gln Phe Pro Gln His Ser Phe 165 170 175 Lys His Glu Asp Pro Met Gly Gln Gln Gly Ser Leu Gly Glu Gln Gln 180 185 190 Tyr Ser Val Pro Pro Pro Val Tyr Gly Cys His Thr Pro Thr Asp Ser 195 200 205 Cys Thr Gly Ser Gln Ala Leu Leu Leu Arg Thr Pro Tyr Ser Ser Asp 210 215 220 Asn Leu Tyr Gln Met Thr Ser Gln Leu Glu Cys Met Thr Trp Asn Gln 225 230 235 240 Met Asn Leu Gly Ala Thr Leu Lys Gly Met Ala Ala Gly Ser Ser Ser 245 250 255 Ser Val Lys Trp Thr Glu Gly Gln Ser Asn His Gly Ile Gly Tyr Glu 260 265 270 Ser Glu Asn His Thr Ala Pro Ile Leu Cys Gly Ala Gln Tyr Arg Ile 275 280 285 His Thr His Gly Val Phe Arg Gly Ile Gln Asp Val Arg Arg Val Ser 290 295 300 Gly Val Ala Pro Thr Leu Val Arg Ser Ala Ser Glu Thr Ser Glu Lys 305 310 315 320 Arg Pro Phe Met Cys Ala Tyr Pro Gly Cys Asn Lys Arg Tyr Phe Lys 325 330 335 Leu Ser His Leu Gln Met His Ser Arg Lys His Thr Gly Glu Lys Pro 340 345 350 Tyr Gln Cys Asp Phe Lys Asp Cys Glu Arg Arg Phe Ser Arg Ser Asp 355 360 365 Gln Leu Lys Arg His Gln Arg Arg His Thr Gly Val Lys Pro Phe Gln 370 375 380 Cys Lys Thr Cys Gln Arg Lys Phe Ser Arg Ser Asp His Leu Lys Thr 385 390 395 400 His Thr Arg Thr His Thr Gly Lys Thr Ser Glu Lys Pro Phe Ser Cys 405 410 415 Arg Trp His Ser Cys Gln Lys Lys Phe Ala Arg Ser Asp Glu Leu Val 420 425 430 Arg His His Asn Met His Gln Arg Asn Met Thr Lys Leu His Val Ala 435 440 445 Leu 449 2 9 PRT Artificial Sequence Synthetic Peptide 2 Cys Met Thr Trp Asn Gln Met Asn Leu 1 5 3 9 PRT Artificial Sequence Synthetic Peptide 3 Cys Tyr Thr Trp Asn Gln Met Asn Leu 1 5 4 9 PRT Artificial Sequence Antigenic Peptide 4 Ala Tyr Gly Leu Asp Phe Tyr Ile Leu 1 5

Claims (7)

1. A cancer antigen peptide having for its active ingredient a peptide consisting of 9-30 amino acids and comprising the following amino acid sequence: Cys Tyr Thr Trp Asn Gln Met Asn Leu (Sequence ID No. 3).
2. A cancer antigen peptide according to claim 1 that is consisted of 9-12 amino acids and comprises the amino acid sequence indicated in Sequence ID No. 3.
3. A cancer antigen peptide according to claim 1 that is consisted of the amino acid sequence indicated in Sequence ID No. 3.
4. A cancer vaccine having for its active ingredient a peptide according to any of claims 1 through 3.
5. A DNA vaccine against cancer having for its active ingredient DNA that codes for a peptide according to any of claims 1 through 3.
6. Antigen-presenting cells on which are presented a complex of HLA antigen and a peptide according to any of claims 1 through 3.
7. Cytotoxic T-cells that recognize a complex of HLA antigen and a peptide according to any of claims 1 through 3.
US10/471,835 2001-03-22 2002-03-22 Wt1 modified peptide Abandoned US20040097703A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/552,660 US8105604B2 (en) 2001-03-22 2009-09-02 WT1 modified peptide

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001-83250 2001-03-22
JP2001083250 2001-03-22
PCT/JP2002/002794 WO2002079253A1 (en) 2001-03-22 2002-03-22 Wti modified peptide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/552,660 Continuation US8105604B2 (en) 2001-03-22 2009-09-02 WT1 modified peptide

Publications (1)

Publication Number Publication Date
US20040097703A1 true US20040097703A1 (en) 2004-05-20

Family

ID=18939092

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/471,835 Abandoned US20040097703A1 (en) 2001-03-22 2002-03-22 Wt1 modified peptide
US12/552,660 Expired - Fee Related US8105604B2 (en) 2001-03-22 2009-09-02 WT1 modified peptide

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/552,660 Expired - Fee Related US8105604B2 (en) 2001-03-22 2009-09-02 WT1 modified peptide

Country Status (13)

Country Link
US (2) US20040097703A1 (en)
EP (1) EP1371664B1 (en)
JP (2) JP3728439B2 (en)
KR (1) KR100863853B1 (en)
CN (1) CN1281625C (en)
AT (1) ATE383375T1 (en)
BR (1) BRPI0208183B8 (en)
CA (1) CA2440303C (en)
DE (1) DE60224508T2 (en)
ES (1) ES2298353T3 (en)
HK (1) HK1070078A1 (en)
TW (1) TWI318630B (en)
WO (1) WO2002079253A1 (en)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6815291B2 (en) 2002-02-20 2004-11-09 Seiko Epson Corporation Method of manufacturing semiconductor device
US20040247609A1 (en) * 2001-09-28 2004-12-09 Haruo Sugiyama Novel method of inducing antigen-specific t cells
US20050002951A1 (en) * 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
US20050266014A1 (en) * 1998-07-31 2005-12-01 Haruo Sugiyama Tumor antigen based on products of the tumor suppressor gene WT1
US20060205667A1 (en) * 2002-09-20 2006-09-14 Haruo Sugiyama Wt1 substitution pepides
US20060217297A1 (en) * 2003-01-15 2006-09-28 Haruo Sugiyama Dimerized peptide
US20070036808A1 (en) * 2002-09-12 2007-02-15 Haruo Sugiyama Cancer antigen peptide formulations
US7420034B2 (en) 2002-06-12 2008-09-02 Dainippon Sumitomo Pharma Co., Ltd. HLA-A24-restricted cancer antigen peptides
US20090325886A1 (en) * 2001-03-22 2009-12-31 International Institute Of Cancer Immunology, Inc Wt1 modified peptide
US20100062013A1 (en) * 2004-03-31 2010-03-11 International Institute Of Cancer Immunology, Inc. Cancer antigen peptides derived from wt1
US20100062010A1 (en) * 2005-11-30 2010-03-11 International Institute Of Cancer Immunology, Inc. Novel peptide compound
US20160009781A1 (en) 2012-09-12 2016-01-14 International Institute Of Cancer Immunology, Inc. Antigen-specific helper t-cell receptor genes
US9663563B2 (en) 2013-03-12 2017-05-30 Sumitomo Dainippon Pharma Co., Ltd. Aqueous liquid composition
US9803246B2 (en) 2011-06-28 2017-10-31 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific T cell
US9833493B2 (en) 2012-12-17 2017-12-05 International Institute Of Cancer Immunology, Inc. Method for activating helper T cell
US10093977B2 (en) 2007-03-05 2018-10-09 International Institute Of Cancer Immunology, Inc. Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them
US10124046B2 (en) 2003-11-05 2018-11-13 International Institute Of Cancer Immunology, Inc. HLA-DR-binding antigen peptide derived from WT1
US10139395B2 (en) 2007-02-27 2018-11-27 International Institute Of Cancer Immunology, Inc. Method for activation of helper T cell and composition for use in the method
US10253075B2 (en) 2014-02-26 2019-04-09 tella, Inc. WT1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
US10426822B2 (en) 2007-12-05 2019-10-01 International Institute Of Cancer Immunology, Inc. Cancer vaccine composition
US10471136B2 (en) 2014-09-27 2019-11-12 Sumitomo Dainippon Pharma Co., Ltd. Pharmaceutical composition for injection
US10500257B2 (en) 2003-06-27 2019-12-10 International Institute Of Cancer Immunology, Inc. Method of selecting WT1 vaccine adaptive patient
US10588952B2 (en) 2013-03-29 2020-03-17 Sumitomo Dainippon Pharma Co., Ltd. Conjugate vaccine using trimming function of ERAP1
US10654892B2 (en) 2010-10-05 2020-05-19 International Institute Of Cancer Immunology, Inc. Method for activating helper T cell
US11759509B2 (en) 2013-03-29 2023-09-19 Sumitomo Pharma Co., Ltd. WT1 antigen peptide conjugate vaccine

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009511637A (en) 2005-10-17 2009-03-19 スローン−ケターリング インスティチュート フォー キャンサー リサーチ HLA class II binding WT1 peptide and composition thereof
CA2638122A1 (en) * 2006-02-22 2007-08-30 International Institute Of Cancer Immunology, Inc. Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same
EP3117836A1 (en) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and uses thereof
EP3026115B1 (en) * 2006-12-28 2017-05-17 International Institute of Cancer Immunology, Inc. Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
US9539299B2 (en) * 2011-10-27 2017-01-10 International Institute Of Cancer Immunology, Inc. Combination therapy with WT1 peptide vaccine and temozolomide
CN108676069A (en) 2012-01-13 2018-10-19 纪念斯隆凯特林癌症中心 Immunogenicity WT-1 peptides and its application method
US20150150975A1 (en) 2012-07-02 2015-06-04 Sumitomo Dainippon Pharma Co., Ltd. Transdermal cancer antigen peptide preparation
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
AU2014207615B2 (en) * 2013-01-15 2018-11-01 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
JP6250288B2 (en) * 2013-01-30 2017-12-20 株式会社医学生物学研究所 T cell receptor and use thereof
JP6512567B2 (en) 2013-02-05 2019-05-15 日東電工株式会社 WT1 peptide cancer vaccine composition for transdermal administration
CN103961307B (en) 2013-02-05 2019-11-29 日东电工株式会社 For percutaneous administration of with WT1 peptide cancer vaccine composition
JP6497691B2 (en) 2013-02-05 2019-04-10 日東電工株式会社 WT1 peptide cancer vaccine composition for mucosal administration
KR102050931B1 (en) 2013-02-05 2019-12-02 닛토덴코 가부시키가이샤 Tape preparation of wt1 peptide cancer vaccine for transdermal administration
ES2954899T3 (en) 2013-05-13 2023-11-27 Int Inst Cancer Immunology Inc Procedure to predict the clinical effect of an immunotherapy
JP7209963B2 (en) 2016-11-30 2023-01-23 住友ファーマ株式会社 WT1 helper peptide and its combination with cancer antigen peptide conjugate
JPWO2018181648A1 (en) 2017-03-30 2020-02-13 大日本住友製薬株式会社 WT1 cancer antigen peptide and peptide conjugate containing the same
AU2019349329A1 (en) 2018-09-28 2021-04-29 Sumitomo Pharma Co., Ltd. Injectable composition
AU2019352354A1 (en) 2018-10-05 2021-05-13 International Institute Of Cancer Immunology, Inc. Prophylactic or therapeutic drug for benign tumor
TW202045528A (en) 2019-02-28 2020-12-16 日商大日本住友製藥股份有限公司 Method for selecting subject likely benefiting from pharmaceutical composition for treating or preventing cancer
KR20230009426A (en) 2020-05-12 2023-01-17 스미토모 파마 가부시키가이샤 Pharmaceutical composition for treating cancer
CN111647066B (en) * 2020-07-01 2020-12-18 维肽瀛(上海)生物技术有限公司 WT1 polypeptide tumor inhibitor
AU2022327884A1 (en) 2021-08-12 2024-02-22 International Institute Of Cancer Immunology, Inc. Pharmaceutical composition and method for treatment or prevention of cancer

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034235A (en) * 1995-06-01 2000-03-07 Tadamitsu Kishimoto Growth inhibitor for leukemia cell comprising antisense oligonucleotide derivative to wilms tumor gene (WT1)
US6207880B1 (en) * 1995-09-19 2001-03-27 Planttec Biotechnologie Gmbh Plants which synthesize a modified starch, process for the production thereof and modified starch
US20030039635A1 (en) * 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US20030082196A1 (en) * 2000-10-09 2003-05-01 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US20030092656A1 (en) * 1997-07-16 2003-05-15 Haruo Sugiyama Therapeutic agents for treatment of solid tumors comprising an expression-inhibiting sustance against Wilms' tumor gene (WT1)
US20030095971A1 (en) * 1998-09-30 2003-05-22 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030198622A1 (en) * 1998-09-30 2003-10-23 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030215458A1 (en) * 1998-09-30 2003-11-20 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20040018204A1 (en) * 2001-08-24 2004-01-29 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20040247609A1 (en) * 2001-09-28 2004-12-09 Haruo Sugiyama Novel method of inducing antigen-specific t cells
US20050002951A1 (en) * 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
US20050266014A1 (en) * 1998-07-31 2005-12-01 Haruo Sugiyama Tumor antigen based on products of the tumor suppressor gene WT1

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6122018A (en) 1984-07-06 1986-01-30 Green Cross Corp:The Enhancer for cancer immunotherapy
DE69033127T2 (en) 1989-11-13 1999-10-14 Massachusetts Inst Technology LOCALIZATION AND CHARACTERIZATION OF THE WILMS TUMOR GENE
WO1995016464A1 (en) 1993-12-14 1995-06-22 Johns Hopkins University School Of Medicine Controlled release of pharmaceutically active substances for immunotherapy
US5622835A (en) 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
PT772619E (en) 1994-07-15 2006-10-31 Univ Iowa Res Found OLIGONUCLEOTIDOS IMUNOMODULADORES
JP3904260B2 (en) 1995-06-01 2007-04-11 岸本 忠三 Leukemia cell growth inhibitor comprising an antisense oligonucleotide derivative against Wilms tumor gene (WT1)
JP4789095B2 (en) 1997-07-16 2011-10-05 治夫 杉山 Solid tumor therapeutic agent comprising an expression inhibitor against Wilms tumor gene (WT1)
US5985264A (en) 1998-03-05 1999-11-16 The Medical College Of Ohio IL-12 Stimulation of Neonatal immunity
BR9914116A (en) * 1998-09-30 2002-01-15 Corixa Corp Compositions and methods for wt1-specific immunotherapy
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
CN1391482A (en) 1999-01-12 2003-01-15 史密丝克莱恩比彻姆生物有限公司 Therapy
SI1031346T1 (en) 1999-01-27 2002-08-31 Idea Ag Noninvasive vaccination through the skin
EP1681064A1 (en) 1999-07-22 2006-07-19 Dainippon Sumitomo Pharma Co., Ltd. Induction of antigen-specific T cells by interferon
JP2001089389A (en) 1999-07-22 2001-04-03 Sumitomo Pharmaceut Co Ltd Inducer for antigen-specific t cell
EP1261711A2 (en) 2000-02-22 2002-12-04 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
TWI318630B (en) 2001-03-22 2009-12-21 Int Inst Cancer Immunology Inc Wt1 modified peptide
AU2003242305A1 (en) * 2002-06-12 2003-12-31 Chugai Seiyaku Kabushiki Kaisha Hla-a24-restricted cancer antigen peptide
EP1550453B1 (en) * 2002-09-12 2015-05-27 International Institute of Cancer Immunology, Inc. Cancer antigen peptide preparation
DE60329201D1 (en) * 2002-09-20 2009-10-22 Chugai Pharmaceutical Co Ltd SUBSTITUTED WT1 PEPTIDES
CN101851275A (en) * 2003-01-15 2010-10-06 株式会社国际癌症免疫研究所 Dimerized peptide
ES2443582T3 (en) 2003-06-27 2014-02-19 International Institute Of Cancer Immunology, Inc. Method for diagnosing cancer comprising the measurement of WT1-specific CTL precursor cells
US20080070835A1 (en) 2003-11-05 2008-03-20 International Institute Of Cancer Immunology, Inc Hla-Dr-Binding Antigen Peptide Derived From Wt1
DK1731605T3 (en) 2004-03-31 2010-05-25 Int Inst Cancer Immunology Inc Cancer antigen peptides derived from WT1

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034235A (en) * 1995-06-01 2000-03-07 Tadamitsu Kishimoto Growth inhibitor for leukemia cell comprising antisense oligonucleotide derivative to wilms tumor gene (WT1)
US6207880B1 (en) * 1995-09-19 2001-03-27 Planttec Biotechnologie Gmbh Plants which synthesize a modified starch, process for the production thereof and modified starch
US20030092656A1 (en) * 1997-07-16 2003-05-15 Haruo Sugiyama Therapeutic agents for treatment of solid tumors comprising an expression-inhibiting sustance against Wilms' tumor gene (WT1)
US20050266014A1 (en) * 1998-07-31 2005-12-01 Haruo Sugiyama Tumor antigen based on products of the tumor suppressor gene WT1
US20030095971A1 (en) * 1998-09-30 2003-05-22 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US20030198622A1 (en) * 1998-09-30 2003-10-23 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030215458A1 (en) * 1998-09-30 2003-11-20 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20040126362A1 (en) * 1998-09-30 2004-07-01 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030039635A1 (en) * 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030082196A1 (en) * 2000-10-09 2003-05-01 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US20040018204A1 (en) * 2001-08-24 2004-01-29 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20040247609A1 (en) * 2001-09-28 2004-12-09 Haruo Sugiyama Novel method of inducing antigen-specific t cells
US20050002951A1 (en) * 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7390871B2 (en) 1998-07-31 2008-06-24 International Institute Of Cancer Immunology, Inc. Tumor antigen based on products of the tumor suppressor gene WT1
US20090143291A1 (en) * 1998-07-31 2009-06-04 International Institute Of Cancer Immunology, Inc. Tumor antigen based on products of the tumor suppressor gene wt1
US20090281043A1 (en) * 1998-07-31 2009-11-12 International Institute Of Cancer Immunology, Inc. Tumor antigen based on products of the tumor suppressor gene wt1
US20050266014A1 (en) * 1998-07-31 2005-12-01 Haruo Sugiyama Tumor antigen based on products of the tumor suppressor gene WT1
US7030212B1 (en) 1998-07-31 2006-04-18 Haruo Sugiyama Tumor antigen based on products of the tumor suppressor gene WT1
US20060093615A1 (en) * 1998-07-31 2006-05-04 Haruo Sugiyama Tumor antigen based on products of the tumor suppressor gent WT1
US7807792B2 (en) 1998-07-31 2010-10-05 International Institute Of Cancer Immunology, Inc. Tumor antigen based on products of the tumor suppressor gene WT1
US9403886B2 (en) 1998-07-31 2016-08-02 International Institute Of Cancer Immunology, Inc. Tumor antigen based on products of the tumor suppressor gene WT1
US7517950B2 (en) 1998-07-31 2009-04-14 International Institute Of Cancer Immunology, Inc. Tumor antigen based on products of the tumor suppressor gene WT1
US7608685B1 (en) 1998-07-31 2009-10-27 International Institute Of Cancer Immunology, Inc. Tumor antigen based on products of the tumor suppressor gene WT1
US8105604B2 (en) 2001-03-22 2012-01-31 International Institute Of Cancer Immunology, Inc. WT1 modified peptide
US20090325886A1 (en) * 2001-03-22 2009-12-31 International Institute Of Cancer Immunology, Inc Wt1 modified peptide
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
US20050002951A1 (en) * 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
US20040247609A1 (en) * 2001-09-28 2004-12-09 Haruo Sugiyama Novel method of inducing antigen-specific t cells
US6815291B2 (en) 2002-02-20 2004-11-09 Seiko Epson Corporation Method of manufacturing semiconductor device
US7420034B2 (en) 2002-06-12 2008-09-02 Dainippon Sumitomo Pharma Co., Ltd. HLA-A24-restricted cancer antigen peptides
US20090099090A1 (en) * 2002-06-12 2009-04-16 Sumitomo Pharmaceuticals Company, Limited Hla-a24-restricted cancer antigen peptides
US7666985B2 (en) 2002-06-12 2010-02-23 International Institute Of Cancer Immunology, Inc. HLA-A24-restricted cancer antigen peptides
US20090263409A1 (en) * 2002-09-12 2009-10-22 International Institute Of Cancer Immunology, Inc Cancer antigen peptide formulations
US7342092B2 (en) 2002-09-12 2008-03-11 International Institute Of Cancer Immunology, Inc. Cancer antigen peptide formulations
US20070036808A1 (en) * 2002-09-12 2007-02-15 Haruo Sugiyama Cancer antigen peptide formulations
US7378384B2 (en) 2002-09-20 2008-05-27 International Institute Of Cancer Immunology, Inc. WT1 substitution peptides
US20060205667A1 (en) * 2002-09-20 2006-09-14 Haruo Sugiyama Wt1 substitution pepides
US8242084B2 (en) 2003-01-15 2012-08-14 Chugai Seiyaku Kabushiki Kaisha Dimerized peptide
US20060217297A1 (en) * 2003-01-15 2006-09-28 Haruo Sugiyama Dimerized peptide
US10500257B2 (en) 2003-06-27 2019-12-10 International Institute Of Cancer Immunology, Inc. Method of selecting WT1 vaccine adaptive patient
US11027003B2 (en) 2003-11-05 2021-06-08 International Institute Of Cancer Immunology, Inc. HLA-DR-binding antigen peptide derived from WT1
US10124046B2 (en) 2003-11-05 2018-11-13 International Institute Of Cancer Immunology, Inc. HLA-DR-binding antigen peptide derived from WT1
US8388975B2 (en) 2004-03-31 2013-03-05 International Institute Of Cancer Immunology, Inc. Cancer antigen peptides derived from WT1
US20100062013A1 (en) * 2004-03-31 2010-03-11 International Institute Of Cancer Immunology, Inc. Cancer antigen peptides derived from wt1
US9273148B2 (en) 2005-11-30 2016-03-01 International Institute Of Cancer Immunology, Inc. Method for cancer immunotherapy
US20100062010A1 (en) * 2005-11-30 2010-03-11 International Institute Of Cancer Immunology, Inc. Novel peptide compound
US9765114B2 (en) 2005-11-30 2017-09-19 International Institute Of Cancer Immunology, Inc. Method for cancer immunotherapy
US7939627B2 (en) * 2005-11-30 2011-05-10 International Institute of Cancer Immunology Peptides comprising an epitope of the wilms tumor gene product
US8575308B2 (en) 2005-11-30 2013-11-05 International Institute of Cancer Immunology Method for cancer immunotherapy
US20110229506A1 (en) * 2005-11-30 2011-09-22 International Institute Of Cancer Immunology, Inc. Method for cancer immunotherapy
US11555814B2 (en) 2007-02-27 2023-01-17 International Institute Of Cancer Immunology, Inc. Method for activation of helper t cell and composition for use in the method
US10139395B2 (en) 2007-02-27 2018-11-27 International Institute Of Cancer Immunology, Inc. Method for activation of helper T cell and composition for use in the method
US10669584B2 (en) 2007-03-05 2020-06-02 International Institute Of Cancer Immunology, Inc. Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them
US10093977B2 (en) 2007-03-05 2018-10-09 International Institute Of Cancer Immunology, Inc. Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them
US11707512B2 (en) 2007-12-05 2023-07-25 International Institute Of Cancer Immunology, Inc. Cancer vaccine composition
US10426822B2 (en) 2007-12-05 2019-10-01 International Institute Of Cancer Immunology, Inc. Cancer vaccine composition
US10654892B2 (en) 2010-10-05 2020-05-19 International Institute Of Cancer Immunology, Inc. Method for activating helper T cell
US10648036B2 (en) 2011-06-28 2020-05-12 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific T cell
US9803246B2 (en) 2011-06-28 2017-10-31 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific T cell
US10815288B2 (en) 2012-09-12 2020-10-27 International Institute Of Cancer Immunology, Inc. Antigen-specific helper T-cell receptor genes
US11091531B2 (en) 2012-09-12 2021-08-17 International Institute Of Cancer Immunology, Inc. Antigen-specific helper T-cell receptor genes
US20160009781A1 (en) 2012-09-12 2016-01-14 International Institute Of Cancer Immunology, Inc. Antigen-specific helper t-cell receptor genes
US9833493B2 (en) 2012-12-17 2017-12-05 International Institute Of Cancer Immunology, Inc. Method for activating helper T cell
US9663563B2 (en) 2013-03-12 2017-05-30 Sumitomo Dainippon Pharma Co., Ltd. Aqueous liquid composition
US10588952B2 (en) 2013-03-29 2020-03-17 Sumitomo Dainippon Pharma Co., Ltd. Conjugate vaccine using trimming function of ERAP1
US11759509B2 (en) 2013-03-29 2023-09-19 Sumitomo Pharma Co., Ltd. WT1 antigen peptide conjugate vaccine
US10253075B2 (en) 2014-02-26 2019-04-09 tella, Inc. WT1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
US10471136B2 (en) 2014-09-27 2019-11-12 Sumitomo Dainippon Pharma Co., Ltd. Pharmaceutical composition for injection

Also Published As

Publication number Publication date
CA2440303A1 (en) 2002-10-10
BRPI0208183B1 (en) 2018-08-28
WO2002079253A1 (en) 2002-10-10
KR20030084970A (en) 2003-11-01
JPWO2002079253A1 (en) 2004-07-22
BRPI0208183B8 (en) 2021-05-25
EP1371664A4 (en) 2006-03-22
JP3819930B2 (en) 2006-09-13
CN1281625C (en) 2006-10-25
DE60224508T2 (en) 2008-12-24
JP3728439B2 (en) 2005-12-21
US20090325886A1 (en) 2009-12-31
JP2006034296A (en) 2006-02-09
DE60224508D1 (en) 2008-02-21
EP1371664A1 (en) 2003-12-17
US8105604B2 (en) 2012-01-31
EP1371664B1 (en) 2008-01-09
ATE383375T1 (en) 2008-01-15
CA2440303C (en) 2013-03-19
BR0208183A (en) 2004-03-02
KR100863853B1 (en) 2008-10-15
ES2298353T3 (en) 2008-05-16
CN1531553A (en) 2004-09-22
TWI318630B (en) 2009-12-21
HK1070078A1 (en) 2005-06-10

Similar Documents

Publication Publication Date Title
US8105604B2 (en) WT1 modified peptide
US7390871B2 (en) Tumor antigen based on products of the tumor suppressor gene WT1
EP2270042B1 (en) KDR peptides and vaccines comprising the same
KR20130026527A (en) Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
KR20120030380A (en) Cancer antigen helper peptide
CA2451846A1 (en) Cancer vaccine comprizing a cancer antigen based on the product of a tumor suppressor gene wt1 and a cationic liposome
KR20060129393A (en) Epitope/peptide recognized by hla-a2402-restricted ep-cam-specific ctl and use of the same

Legal Events

Date Code Title Description
AS Assignment

Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SUGIYAMA, HARUO;REEL/FRAME:018192/0207

Effective date: 20060806

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION